AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer

Prior treatment

• 1\. Refuse chemotherapy or surgery;
• 5\. Undergone major surgery within 30 days;
• 6\. Participated in other drug related clinical trials within 4 weeks;
• 9\. Failure to recover from treatment-related toxicity to ≤ grade 1 (adverse events such as alopecia judged by the researcher not to affect the treatment with the research drug are excluded);

Other illness

• 3\. History of other malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);
• 4\. Accompanied by other serious diseases, including but not limited to: compensatory heart failure (NYHA grade III and IV), unstable angina, poorly controlled arrhythmias, uncontrolled hypertension (SBP\>160mmHg or DBP\>100mmHg); active infections; unmanageable diabetes mellitus; presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage; severe portal hypertension; gastric outlet obstruction; Respiratory insufficiency;
• 7\. Known allergy to prescription or any component of the prescription used in this study;
• 8\. With HIV, or active hepatitis (hepatitis B, hepatitis C);

Other

• 2\. Other part (e.g. peritoneum, lung, bone, brain) metastasis;
• 10.Other reasons that are not suitable to participate in this study according to the researcher's judgment.

• 1\. Age 18-75 years old, gender unlimited;
• 2\. Histologically or cytologically confirmed pancreatic cancer;
• 3\. Confirmed as locally advanced pancreatic cancer by CT/MRI imaging, with no evidence of distant metastasis;
• 4\. No prior chemotherapy or other tumor systemic therapy;
• 5\. Measurable disease according to RECIST criteria v1.1;
• 6\. Adequate organ and bone marrow function, defined as follows: hemoglobin≥9.0 g/dL; absolute neutrophil count (ANC)≥1.5×10\^9/L; platelets≥100×10\^9/L; serum total bilirubin (TBIL)≤1.5×ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of normal (ULN); serum creatinine≤1.5×ULN or estimated creatinine clearance \> 60 mL/min;
• 7\. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 2;
• 8\. Life expectancy is expected to be ≥3 months;
• 9\. Fertile subjects are willing to take contraceptive measures during the study period.
• 10\. Good compliance and signed informed consent voluntarily.